| (Values in U.S. Thousands) | Dec, 2016 | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 |
| Sales | -9,999,000 | 46,020 | 68,130 | 35,600 | 36,510 |
| Sales Growth | -21,827.51% | -32.45% | +91.38% | -2.49% | +25.59% |
| Net Income | -9,999,000 | -27,830 | 109,850 | -53,790 | -59,870 |
| Net Income Growth | -35,828.86% | -125.33% | +304.22% | +10.16% | -7.97% |
Ariad Pharm Inc (ARIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.
Fiscal Year End Date: 12/31